Skip to Main Content

Eli Lilly said Thursday that a study showed its experimental diabetes drug, tirzepatide, reduced patients’ blood sugar and body weight more than a rival medicine, Novo Nordisk’s Ozempic.

Investors had been nervously awaiting the result, which was reported in a press release.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!


Comments are closed.